Fifth Third Wealth Advisors’s Cytokinetics CYTK Stock Holding History

Fifth Third Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$439K	Buy	5,154 +1,830	+55%	+$131K	0.01%	546
2026 Q1	$219K	Buy	3,324 +115	+4%	+$7.31K	0.01%	756
2025 Q4	$204K	Buy	+3,209	New	+$200K	0.01%	757

Other funds holding CYTK

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Fifth Third Wealth Advisors's CYTK Position: Q2 2026 in Review

Fifth Third Wealth Advisors increased its Cytokinetics (CYTK) stake by 55% in Q2 2026, buying an estimated $131K and bringing the position to 5,154 shares worth $439K. The position accounts for 0.01% of the portfolio, ranked #546.

Fifth Third Wealth Advisors first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Fifth Third Wealth Advisors held 5,154 shares of Cytokinetics worth $439K as of Q2 2026.
Fifth Third Wealth Advisors bought 1,830 Cytokinetics shares in Q2 2026, an estimated $131K.
Cytokinetics made up 0.01% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #546 holding.
Fifth Third Wealth Advisors first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
47 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.